跳至主要内容
临床试验/NL-OMON54546
NL-OMON54546招募中不适用

Implementation of pharmacokinetic-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand disease - OPTI-CLOT: To Wi

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 160 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 99(—)

入选标准

  • - No minimum or maximum age at inclusion date;
  • - Hemorrhagic symptoms or a family history of von Willebrand disease with
  • historically lowest levels of VWF:Ag <0.60 IU/ml and/or VWF:Act <0.60 IU/ml
  • and/or VWF:CB <0.60 and/or FVIII <0.40 IU/ml;
  • - Need for DDAVP-testing (arm A); and/or
  • - Need for a medical intervention requiring DDAVP and/or VWF replacement
  • therapy (arm B) (arm B); or
  • - (Future) Bleeding requiring DDAVP and/or VWF replacement therapy (arm C); or
  • - Receiving or requiring prophylaxis with VWF-containing concentrate due severe
  • and/or recurrent bleeding episode (arm D).
  • - Written patient (and in case of a patient <16 years of age, parental)
  • informed consent.

排除标准

  • - Any other known hemostatic abnormalities;
  • - Acquired VWD;
  • - Presence of VWF antibodies (>0.2 BU)
  • - Withdrawal of (parental) informed consent.

研究者

相似试验